港股異動 | 神威藥業漲近5% 旗下中藥產品迎來政策利好
格隆匯10月30日丨神威藥業(2877.HK)漲近5%,報7.69港元,成交536.5萬港元,總市值63.6億港元。

習近平近日對中醫藥工作作出重要指示強調,要遵循中醫藥發展規律,傳承精華,守正創新,加快推進中醫藥現代化、產業化,堅持中西醫並重,推動中醫藥和西醫藥相互補充、協調發展,推動中醫藥事業和產業高質量發展,推動中醫藥走向世界,充分發揮中醫藥防病治病的獨特優勢和作用。神威藥業是河北省第一家中藥配方顆粒生產企業。近兩年來,神威中藥配方顆粒在醫療機構內受到了醫生及患者的普遍歡迎和好評,市場規模迅速擴大,成為企業新的業績增長極。神威藥業也是中國現代中藥注射劑、軟膠囊的領先製造商,主要產品分為中藥注射液、中藥軟膠囊、中藥顆粒三大類。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.